Explore our comprehensive coverage of metabolic health, including scientific research, policy developments, environmental impacts, and solutions for a sustainable future.
The FDA's OTC triple-agonist approval, the WHO's microplastic sarcopenia report, the Peloton-Tonal biomarker joint venture, the FTC's bio-hacking crac...
Read Full Story →
Nutrition & FitnessThe FDA's new warnings on triple-agonist weight loss drugs regarding severe lean muscle depletion ar...
Healthcare PolicyThe convergence of GLP-1 coverage restrictions, MAHA movement influence, and employer plan expansion...
Nutrition & FitnessThe FDA's approval of triple-agonist retatrutide, WADA's ban on non-peptide myostatin inhibitors, an...
Nutrition & FitnessThe convergence of triple-agonist therapeutics, aggressive ultra-processed food taxation, and contin...
Nutrition & FitnessThe September 2026 convergence of FDA GLP-1 mandates, the WHO's UPF report, and the NCAA's stimulant...
Nutrition & FitnessElite athletes and Hollywood figures are increasingly integrating GLP-1 agonists into their regimens...
